Effects of α‐tocopherol and β‐carotene supplementation on cancer incidence and mortality: 18‐Year postintervention follow‐up of the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention Study

In the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention Study among 29,133 Finnish male smokers aged 50–69 years, daily α‐tocopherol (50 mg) for a median of 6.1 years decreased the risk of prostate cancer, whereas β‐carotene (20 mg) increased risk of lung cancer and overall mortality. To determine the postintervention effects of α‐tocopherol and β‐carotene, 25,563 men were followed 18 years for cancer incidence and all causes of mortality through national registers. Neither supplement had significant effects on post‐trial cancer incidence. Relative risk (RR) for lung cancer (n = 2,881) was 1.04 (95% confidence interval [CI], 0.96–1.11) among β‐carotene recipients compared with nonrecipients. For prostate cancer (n = 2,321), RR was 0.97 (95% CI, 0.89–1.05) among α‐tocopherol recipients compared with nonrecipients with the preventive effect of α‐tocopherol continuing ∼8 years postintervention. Body mass index significantly modified the effect of α‐tocopherol on prostate cancer (p for interaction = 0.01) RR 1.00 (95% CI, 0.88–1.14) in normal‐weight men, 0.87 (95% CI, 0.77–0.98) in overweight men, and 1.25 (95% CI, 1.01–1.55) in obese men. The post‐trial relative mortality (based on 16,686 deaths) was 1.02 (95% CI, 0.98–1.05) for α‐tocopherol recipients compared with nonrecipients and 1.02 (95% CI, 0.99–1.05) for β‐carotene recipients compared with nonrecipients. α‐Tocopherol decreased post‐trial prostate cancer mortality (RR, 0.84; 95% CI, 0.70–0.99), whereas β‐carotene increased it (RR, 1.20; 95% CI, 1.01–1.42). In conclusion, supplementation with α‐tocopherol and β‐carotene appeared to have no late effects on cancer incidence. The preventive effect of moderate‐dose α‐tocopherol on prostate cancer continued several years post‐trial and resulted in lower prostate cancer mortality.

[1]  R. Hayes,et al.  Serum α-Tocopherol and γ-Tocopherol Concentrations and Prostate Cancer Risk in the PLCO Screening Trial: A Nested Case-Control Study , 2012, PloS one.

[2]  A. Kong,et al.  Cancer-preventive activities of tocopherols and tocotrienols. , 2010, Carcinogenesis.

[3]  B. Henderson,et al.  Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F2t in serum or urine with prostate cancer risk: the multiethnic cohort , 2009, Cancer Causes & Control.

[4]  J. Manson,et al.  Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. , 2009, Journal of the National Cancer Institute.

[5]  J. Manson,et al.  Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. , 2009, JAMA.

[6]  J. Crowley,et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.

[7]  J. Herman,et al.  Carotenoids and the risk of developing lung cancer: a systematic review. , 2008, The American journal of clinical nutrition.

[8]  F. Berrino,et al.  Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. , 2007, The American journal of clinical nutrition.

[9]  Karla A. Lawson,et al.  Serum and Dietary Vitamin E in Relation to Prostate Cancer Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.

[10]  R. Hayes,et al.  Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. , 2006, Journal of the National Cancer Institute.

[11]  S. Yusuf,et al.  Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. , 2005, JAMA.

[12]  G. Omenn,et al.  The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. , 2004, Journal of the National Cancer Institute.

[13]  Nea Malila,et al.  Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. , 2003, JAMA.

[14]  D. Albanes,et al.  The Finnish Cancer Registry as Follow-Up Source of a Large Trial Cohort , 2002, Acta oncologica.

[15]  D. Albanes,et al.  Effects of long‐term α‐tocopherol supplementation on serum hormones in older men * , 2001 .

[16]  J. Manson,et al.  β-Carotene Supplementation and Incidence of Cancer and Cardiovascular Disease: the Women's Health Study. , 1999, Journal of the National Cancer Institute.

[17]  E. Rimm,et al.  Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  C. Lieber,et al.  Alcohol, vitamin A, and beta-carotene: adverse interactions, including hepatotoxicity and carcinogenicity. , 1999, The American journal of clinical nutrition.

[19]  W. Willett,et al.  Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. , 1999, Cancer research.

[20]  S. Ripatti,et al.  Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. , 1998, Journal of the National Cancer Institute.

[21]  S. Mayne,et al.  Beta-Carotene and lung cancer promotion in heavy smokers--a plausible relationship? , 1996, Journal of the National Cancer Institute.

[22]  M R Cullen,et al.  Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. , 1996, Journal of the National Cancer Institute.

[23]  J. Palmgren,et al.  Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. , 1996, Journal of the National Cancer Institute.

[24]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[25]  J. Manson,et al.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. , 1996, The New England journal of medicine.

[26]  A. Schatzkin,et al.  Antioxidant micronutrients in cancer prevention. , 1991, Hematology/oncology clinics of North America.

[27]  Stefan Sperlich,et al.  Generalized Additive Models , 2014 .

[28]  M. Sporn,et al.  Can dietary beta-carotene materially reduce human cancer rates? , 1981, Nature.

[29]  C. Lawton,et al.  Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .

[30]  Adrianne Bendich,et al.  From 1989 to 2001: what have we learned about the "biological actions of beta-carotene"? , 2004, The Journal of nutrition.

[31]  R. Parker,et al.  Carotenoids in human blood and tissues. , 1989, The Journal of nutrition.

[32]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.